Trial Profile
Efficacy of MK0557 in Combination With Sibutramine or Orlistat
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs MK 0557 (Primary) ; Orlistat; Sibutramine
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 09 May 2014 New trial record